All peptides
Semaglutide
Also known as: Ozempic / Wegovy / Rybelsus
FDA-Approved
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction.
Buy Semaglutide on American Peptides
Affiliate link — we may earn a commission at no extra cost to you.
Overview
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction.
FDA Approval Status
Approved by the FDA for at least one medical indication (see approved uses below).
Mechanism of Action
Activates GLP-1 receptors: enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite.
Current Research
Large randomized trials (SUSTAIN, STEP, SELECT) establish glycemic, weight, and cardiovascular benefits.
Research strength: Strong
Potential Medical Uses
- Type 2 diabetes
- Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
- CV risk reduction
Potential Benefits
- A1C reduction
- Weight loss
- Reduced MACE in trials
Known Side Effects
- Nausea
- Vomiting
- Diarrhea
- Pancreatitis (rare)
- Gallbladder disease
Contraindications
- Personal/family history of medullary thyroid carcinoma
- MEN 2
- Prior hypersensitivity
Drug Interactions
- Insulin/sulfonylureas (hypoglycemia risk)
- Oral medications (delayed absorption)
Administration Methods
- Subcutaneous injection weekly
- Oral tablet (Rybelsus, daily)
Half-life
~7 days
Reconstitution
Prefilled pen; no reconstitution required.
Storage & Handling
Refrigerate unopened pens; in-use pens up to 56 days per label.
References & Sources
Frequently Asked Questions
Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.